cronos group glp-1 receptor agonists weight management diabetes treatments Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies Pharmacogenetics of Glucagon-like-peptide-1 receptor in
Description
58 BW was significantly reduced (up to 4.9% placebo-adjusted, p=0.013) over 4 weeks
J Am Coll Cardiol (2006) 47(8 Suppl):C712
Nat Metab 7 , 12661281 (2025)
P.O., By mouth
It is a question that the team hopes to explore in follow up studies focused specifically on substance use disorder.
